Role of myeloid cells in HIV-1-host interplay
- PMID: 25236811
- PMCID: PMC4366350
- DOI: 10.1007/s13365-014-0281-3
Role of myeloid cells in HIV-1-host interplay
Abstract
The AIDS research field has embarked on a bold mission to cure HIV-1-infected individuals of the virus. To do so, scientists are attempting to identify the reservoirs that support viral persistence in patients on therapy, to understand how viral persistence is regulated and to come up with strategies that interrupt viral persistence and that eliminate the viral reservoirs. Most of the attention regarding the cure of HIV-1 infection has focused on the CD4+ T cell reservoir. Investigators are developing tools to probe the CD4+ T cell reservoirs as well as in vitro systems that provide clues on how to perturb them. By comparison, the myeloid cell, and in particular, the macrophage has received far less attention. As a consequence, there is very little understanding as to the role played by myeloid cells in viral persistence in HIV-1-infected individuals on suppressive therapy. As such, should myeloid cells constitute a viral reservoir, unique strategies may be required for their elimination. This article will overview research that is examining the role of macrophage in virus-host interplay and will discuss features of this interplay that could impact efforts to eliminate myeloid cell reservoirs.
Conflict of interest statement
The author declares that he has no conflict of interest.
Similar articles
-
Colony-Stimulating Factor 1 Receptor Antagonists Sensitize Human Immunodeficiency Virus Type 1-Infected Macrophages to TRAIL-Mediated Killing.J Virol. 2016 Jun 24;90(14):6255-6262. doi: 10.1128/JVI.00231-16. Print 2016 Jul 15. J Virol. 2016. PMID: 27122585 Free PMC article.
-
Irreversible Loss of HIV-1 Proviral Competence in Myeloid Cells upon Suppression of NF-κB Activity.J Virol. 2022 Jun 22;96(12):e0048422. doi: 10.1128/jvi.00484-22. Epub 2022 May 23. J Virol. 2022. PMID: 35604217 Free PMC article.
-
HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies.Cells. 2021 Feb 23;10(2):475. doi: 10.3390/cells10020475. Cells. 2021. PMID: 33672138 Free PMC article. Review.
-
Attacking the HIV reservoir from the immune and viral perspective.Curr HIV/AIDS Rep. 2013 Mar;10(1):33-41. doi: 10.1007/s11904-012-0150-8. Curr HIV/AIDS Rep. 2013. PMID: 23242702 Review.
-
HIV-1 transcriptional regulation in the central nervous system and implications for HIV cure research.J Neurovirol. 2015 Jun;21(3):290-300. doi: 10.1007/s13365-014-0271-5. Epub 2014 Jul 25. J Neurovirol. 2015. PMID: 25060300 Free PMC article. Review.
Cited by
-
Cell-to-Cell Spreading of HIV-1 in Myeloid Target Cells Escapes SAMHD1 Restriction.mBio. 2019 Nov 19;10(6):e02457-19. doi: 10.1128/mBio.02457-19. mBio. 2019. PMID: 31744918 Free PMC article.
-
Cytotoxicity assessment, inflammatory properties, and cellular uptake of Neutraplex lipid-based nanoparticles in THP-1 monocyte-derived macrophages.Nanobiomedicine (Rij). 2017 Dec 21;4:1849543517746259. doi: 10.1177/1849543517746259. eCollection 2017 Jan-Dec. Nanobiomedicine (Rij). 2017. PMID: 29942393 Free PMC article.
-
The Differential Anti-HIV Effect of a New Humic Substance-Derived Preparation in Diverse Cells of the Immune System.Acta Naturae. 2019 Apr-Jun;11(2):68-76. doi: 10.32607/20758251-2019-11-2-68-76. Acta Naturae. 2019. PMID: 31413882 Free PMC article.
-
Host mRNA decay proteins influence HIV-1 replication and viral gene expression in primary monocyte-derived macrophages.Retrovirology. 2019 Feb 7;16(1):3. doi: 10.1186/s12977-019-0465-2. Retrovirology. 2019. PMID: 30732620 Free PMC article.
-
Role of the macrophage in HIV-associated neurocognitive disorders and other comorbidities in patients on effective antiretroviral treatment.J Neurovirol. 2015 Jun;21(3):235-41. doi: 10.1007/s13365-015-0346-y. Epub 2015 May 2. J Neurovirol. 2015. PMID: 25933548 Free PMC article. Review.
References
-
- Alfano M, Graziano F, Genovese L, Poli Macrophage polarization at the crossroad between HIV-1 infection and cancer development. Arterioscler Thromb Vasc Biol. 2013;33:1145–1152. - PubMed
-
- Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487:482–5. - PMC - PubMed
-
- Ayinde D, Casartelli N, Schwartz O. Restricting HIV the SAMHD1 way: through nucleotide starvation. Nat Rev Microbiol. 2012;10:675–80. - PubMed
-
- Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, Wind-Rotolo M, Haggerty CM, Kamireddi AR, Liu Y, Lee J, Persaud D, Gallant JE, Cofrancesco J, Jr, Quinn TC, Wilke CO, Ray SC, Siliciano JD, Nettles RE, Siliciano RF. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol. 2006;80:6441–57. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials